SUMMARY The effect of oral omeprazole on pentagastrin stimulated gastric acid secretion was studied in 11 healthy subjects. Doses of 20-80 mg produced dose dependent inhibition of acid secretion, with total suppression at the highest dose. Omeprazole was absorbed and eliminated from plasma rapidly and the inhibitory effect was related to the area under the plasma concentration time curve. The duration of action was long and single doses of 20 and 40 mg reduced acid secretion significantly for one and three days, respectively. Omeprazole in a dose of 15 mg given once daily for five days, suppressed acid secretion continuously, the inhibitory effect stabilising after three days at a predose inhibition of about 30% and a postdose inhibition of about 80%.
Substituted benzimidazoles inhibit gastric acid secretion in several animal species, both in vitro and in vivo. In vitro data from isolated gastric glands support a novel mechanism of action as substituted benzimidazoles inhibit acid secretion produced by histamine, carbachol, dibutyryl cyclic AMP, and high concentrations of potassium. This suggests an intracellular site of action peripheral to cyclic AMP and close to the acid formation process.1-5 It has been postulated that the gastric proton pump at the secretory membrane of the parietal cell is an enzyme, (H' K+)ATPase, and substituted benzimidazoles appear to interfere with this pump.8 One substituted benzimidazole, H149/94, has been shown to inhibit basal acid output in vivo in man as well as the gastric acid response to pentagastrin stimulation. This effect was dose dependent and long lasting, despite rapid disappearance of H149/94 from the plasma.9
In vitro omeprazole (H168/68) ( Fig. 1) , another substituted benzimidazole, is 10 times more potent than H149/94 on a molar basis. The present studies were designed to evaluate the effects of single and repeated oral doses of omeprazole on pentagastrin stimulated acid secretion in man.
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Sahigren's Hospital, University of Goteborg, S-413 45 Goteborg, Sweden. Received for publication 3 December 1982 Methods SUBJECTS Eleven men median age 29 years (range 22-38 years) and median weight 74 kg (range 63-88 kg) were studied. None had any history suggestive of peptic ulcer disease and all were considered healthy based on a physical examination, ECG, and a laboratory screen. During the first series of experiments the ECG, blood pressure, and pulse rate were recorded, and during all experiments the subjects were asked to report any noted effects. The study was approved by the Ethical Committee of the Medical Faculty, University of Gothenburg, Sweden, and written informed consent was obtained from all subjects. An intravenous infusion of pentagastrin (91 gg/h) over a period of one hour was used to determine the maximal acid response. The response to pentagastrin was restudied during the second hour after drug administration and on the second, third, fourth, and fourteenth day. Each subject received a single dose of placebo, 20 mg and 40 mg of omeprazole according to a latin square design.
REPEATED DOSES
The experiment consisted of two study periods, each lasting five days. Subjects received 15 mg omeprazole daily during one period and placebo during the other, in random order. The maximal acid response to pentagastrin (91 gg/h) was measured before, and during the second hour after, drug/placebo administration on the first, third, and fifth day. On the second and fourth day the subjects remained in the laboratory for one hour after receiving drug/placebo but no acid measurements were performed.
LABORATORY ANALYSIS
Venous blood samples were taken from a peripheral forearm vein before and at frequent intervals after drug administration for omeprazole assay. Plasma concentrations of omeprazole were determined by high pressure liquid chromatography at Department of Analytical Chemistry at AB Hassle. A routine laboratory screen (blood: ESR, Hb, Hct, RBC, WBC, differential count, thrombocytes, ASAT, ALAT, alkaline phosphatase, bilirubin, Na+, K+, Cl-, Ca2 , creatinine, protein, bicarbonate, T3, T4, and TSH; urine: glucose, protein, haemoglobin, and microscopy) was performed before and after each experimental series.
CALCULATIONS AND STATISTICAL ANALYSES
The maximal acid response to the intravenous infusion of pentagastrin (91 1£g/h) was calculated as the sum of the two highest consecutive 15 minute values. To eliminate placebo effects the percentage change in acid secretion was calculated for each subject using the formula:
Linid, Cederberg, Ekenved, Haglund, and Olbe where: a = acid secretion before omeprazole,* b = acid secretion after omeprazole, c = acid secretion before placebo,* d = acid secretion after placebo.
Friedman's two-way analysis of variance and Wilcoxon's two-sided matched pair signed rank test were used to test for drug effects on acid secretion and a coefficient of variation (CV) for differences within individuals was calculated. Significance was claimed if p.005. The area under the plasma concentration-time curve (AUC) extrapolated to infinity was calculated by trapezoidal rule with correction for residual area after the last sample time "' and a correlation coefficient between per cent drug induced inhibition and AUC was calculated after logit transformation where: Y = 1 n R R max -R (R = response as per cent inhibition and R max = 100), and X = loglo AUC. "l The correlation coefficient was tested using Student's t test.
The terminal half-life of omeprazole was calculated by linear regression analysis using the log concentrations measured 60-180 minutes after drug administration. Values are given as mean ± SEM.
Results
Omeprazole produced no side effects or changes in the cardiovascular parameters that were recorded. No drug related effects on the laboratory screen were observed.
Before first omeprazole/placebo dose when repeated doses were given. Omeprazole produced a significant dose dependent inhibition of acid secretion compared with placebo, the mean percentage inhibition being 36±8.5, 65±14.9, 90±5.3, and 99±042% with the 20, 40, 60, and 80 mg doses, respectively. The degree of inhibition remained unchanged throughout the experiment (Fig. 2) (Table 1 ). Omeprazole also reduced the volume secretion but to a lesser extent than acid secretion (21-87%) resulting in a decreased acidity (Table 1 ). Plasma concentrations of omeprazole reached a peak after about 30-40 minutes and then declined with a half-life of about 50 minutes (range 12-82 minutes) (Fig. 3) . The AUC increased with increasing doses and showed a significant correlation with per cent inhibition of acid secretion (R=0.93, p<0.001) (Fig. 4) .
DURATION OF ACTION
During the second hour after omeprazole administration the maximal acid response was reduced by 51±9% and 86±4% respectively, with the 20 and 40 mg doses (Fig. 5, Table 2 ). A significant reduction of 26±12% and 48+9% respectively was still present 24 hours later. With the 20 mg dose, the acid inhibition on the third and fourth days after drug administration (18% and 6% respectively) was not significantly different from placebo but the 40 mg dose of omeprazole continued to produce significant inhibition (34±7% and 18±4% respectively). The first dose of omeprazole (15 mg) produced 47% inhibition of the maximal response to pentagastrin during the second hour after drug administration.
On the third and fifth days before omeprazole, the acid response was reduced by 31% and 37%, respectively. The inhibition during the second hour after dosage on days three and five was 75% and 80% respectively (Fig. 6a,b . Table 3 ). No omeprazole was detectable in plasma before dosage on days three and five. 
Discussion
The histamine H2-blocker cimetidine contain an imidazole ring and the new H2-receptor antagonist ranitidine a furan ring which are similar from a medicinal chemical point of view. 12 Omeprazole and similar benzimidazoles also contain an imidazole ring but reduce acid secretion in a different way.8 Histamine H2-antagonists block the histamine receptor on the parietal cell surface while studies with omeprazole have shown a mechanism of action with intracellular inhibition of the final step of the acid formation process.8 The present study shows that omeprazole is a more potent inhibitor of acid secretion in humans than is H149-94, the only substituted benzimidazole previously used in man, but with a similar inhibitory pattern.9
In these experiments omeprazole was given as a buffered suspension along with repeated doses of sodium bicarbonate and this could have influenced subsequent acid secretion. In the present experiments the stomach was emptied of gastric contents one hour after both drug and placebo administration and, furthermore, the shape of the placebo curve did not change significantly during the second hour (Fig. 2) . This implies that the sodium bicarbonate did not affect acid secretion. An enteric-coated granule formulation, which can be given without sodium bicarbonate, has been developed for future clinical evaluation.
Increasing doses of omeprazole (20-80 mg) produced dose dependent inhibition of submaximal pentagastrin induced acid secretion and total suppression with the highest dose. A single dose of 20 mg omeprazole reduced the maximal acid response to pentagastrin significantly even after 24 hours and with 40 mg of omeprazole there was a slight but significant inhibition of acid secretion three days after dosage. The inhibitory effect was reversible, however, in all subjects which accords with results from animal studies in which the duration of inhibition never exceeded three to four days even with extremely high doses of omeprazole.'3 A maximal pentagastrin dose was used in these experiments to obtain reproducible responses. The coefficient of variation was less than 10% when the test was repeated after 24 hours. When the test was repeated after one hour, however, a reduced response was observed.
Repeated low doses of omeprazole given once daily reduced the maximal acid response to pentagastrin significantly compared with placebo. The predose inhibition -that is, 24 hours after the last dose -as well as the postdose inhibition did not differ significantly between the third and fifth day. This suggests that the inhibitory effect had stabilised after about three days. With this low dose of omeprazole the degree of inhibition varied during a 24 hour period from 30-40% before dosing and 75-80% two hours after a dose. A somewhat greater degree of inhibition might be necessary clinically which could be achieved with a slight increase of daily dose.
Omeprazole was rapidly absorbed and dis- ( Fig. 4 ). An inhibition of volume secretion was also observed but this was less pronounced than the inhibition of acid secretion. As gastric volume secretion is only partly due to parietal cell secretion the smaller reduction could be explained on the basis that omeprazole only affects parietal cell secretion. Substituted benzimidazoles have previously been shown to have a selective action on parietal cell function. In man, single daily doses of omeprazole produce pronounced and long lasting inhibition of gastric acid secretion which could be of clinical benefit in the treatment of peptic ulcer disease. 
